In regulatory news:

The DEA has reduced the amount of almost every Schedule II opioid medication that may be manufactured in the United States in 2017 by 25 percent or more, according to a Final Order recently published in the Federal Register. A handful of medicines were reduced by more, such as hydrocodone, which will be 66 percent of last year’s level. Demand for these opioid medicines, represented by prescriptions written by DEA-registered practitioners, has decreased, likely due to new initiatives to curb nation-wide spikes in opioid addiction and overdose over the last two decades.

Read more here.

Leave a Comment

Your email address will not be published. Required fields are marked *